Involvement of Human Liver Cytochrome P450 3A in Vinblastine Metabolism: Drug Interactions

Cancer Research

Volumn 53, Issue 21, 1993, Pages 5121-5126

  Zhou Pan, Xin Ru ^a,b   Sérée, Eric ^a   Zhou, Xiao Jian ^a,b   Placidi, Michel ^a   Maurel, Patrick ^a   Barra, Yves ^a   Rahmani, Roger ^a  

^a INSERM   (France)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTARABINE; CYTOCHROME P450; DOXORUBICIN; ELLIPTINIUM ACETATE; ERYTHROMYCIN; ETOPOSIDE; FOLINIC ACID; KETOCONAZOLE; LOMUSTINE; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; N DEMETHYLASE; NAVELBINE; POLYCLONAL ANTIBODY; TENIPOSIDE; TROLEANDOMYCIN; URACIL ARABINOSIDE; VINBLASTINE; VINCRISTINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; COMPETITIVE INHIBITION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; FEMALE; GENE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LIVER MICROSOME; MALE; MICHAELIS MENTEN KINETICS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES; BASE SEQUENCE; BINDING, COMPETITIVE; BIOTRANSFORMATION; BLOTTING, WESTERN; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ERYTHROMYCIN; FEMALE; HUMAN; KETOCONAZOLE; KINETICS; MALE; MICROSOMES, LIVER; MIDDLE AGE; MIXED FUNCTION OXYGENASES; MOLECULAR SEQUENCE DATA; MULTIGENE FAMILY; OLIGODEOXYRIBONUCLEOTIDES; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; TROLEANDOMYCIN; VINBLASTINE; VINDESINE;

EID: 0027443019     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Brade, M. Critical review of pharmacology, toxicology, pharmacokinetics of vincristine, vindesine, vinblastine. Proc. Int. Vinca Alkaloids Symp., 6: 95-123, 1980.
2. Rahmani, R., Kleisbauer, J. P., Cano, J. P., Martin, M. and Barbet, J. Clinical pharmacokinetics of vindesine infusion. Cancer Treat. Rep., 69: 839-844, 1985.
3. Rahmani, R., Martin, M., Barbet, J. and Cano, J. P. Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5′-noranhydrovinblastine (navelbine). Cancer Res., 44: 5609-5613, 1984.
4. Rahmani, R., Martin, M., Favre, R., Cano, J. P. and Barbet, J. Clinical pharmacokinetics of vindesine: repeated treatments by intravenous bolus injections. Eur. J. Cancer Clin. Oncol., 29: 1400-1417, 1984.
5. Lengsfeld, A. M., Dietrich, J. and Schultz-Maurer, B. Accumulation and release of vinblastine and vincristine by HeLa cells: light microscopic, cinematographic, and biochemical study. Cancer Res., 42: 3798-3806, 1982.
6. Rahmani, R., Bruno, R., Iliadis, A., Favre, R., Just, S., Barbet, J. and Cano, J. P. Clinical pharmacokinetics of the antitumor drugs navelbine. Cancer Res., 47: 3796-3799, 1987.
7. Gescher, A. and Newell, D. R. The role of pharmacokinetic and metabolism. Studies in anticancer drug discovery and development. In: G. Gilson (ed.), Progress in Drug Metabolism, pp. 263-294. London: Taylor & Francis, 1992.
8. Zhou, X. J. and Rahmani, R. Preclinical and clinical pharmacology of Vinca alkaloids. Drugs, (Suppl. 14): 1-16, 1992.
9. Rahmani, R., Bruno, R., Fabre, G. and Cano, J. P. Extrapolation of preclinical pharmacokinetic data to therapeutic drug use. Xenobiotica, 75(Suppl. 1): 71-88, 1988.
10. Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P. and Meyer, U. A. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (Lond.), 331: 442-46, 1988.
11. Okey, A. B. Enzyme induction in the cytochrome P450 system. Pharmacol. Ther., 45: 241-298, 1990.
12. Murray, M. and Reidy, G. F. Selectivity in the inhibition of mammalian cytochromes P450 by chemical agents. Pharmacol. Rev., 42: 85-101, 1990.
13. Nebert, D. W., Nelson, D. R., Coon, M. J., Estabrook, R. W., Feyereisen, R., Fujii-Kuriyama, Y., Gonzalez, F., Guengerich, F. P., Gunzaluz, I. C., Johnson, E. F., Loper, J. C., Sato, R., Waterman, M. R. and Waxman, D. J. The P450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol., 10: 1-14, 1991.
14. Hadidi, A. H., Coulter, C. E. and Idle, J. R. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients. Cancer Res., 48: 5167-5171, 1988.
15. Sikic, B. I., Ehsan, M. N., Harker, W. G., Friend, N. F., Brown, B. W., Newman, R. A., Hacker, M. P. and Acton, E. M. Dissociation of antitumor potency from anthra-cycline cardiotoxicity in a doxorubicin analog. Science (Washington DC), 228:1544-1546, 1985.
16. Streeter, D. G., Taylor, D. L., Acton, E. M. and Peters, J. H. Comparative cytotoxicities of various morpholinyl anthracyclines. Cancer Chemother. Pharmacol., 14: 160-164, 1985.
17. Van Der Hovoen, T. A. and Coon, M. J. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phos-phate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem., 249: 6302-6310, 1974.
18. Bradford, M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72: 248-254, 1976.
19. Bork, R. W., Muto, T., Beaune, P., Srivastava, P. K., Lloyd, R. S. and Guengerich, F. P., Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J. Biol. Chem., 264: 910-919, 1989.
20. Maniatis, T., Fritsch, E. and Sambrook, J. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
21. Cathala, G., Savouret, J. F., Mendez, B., West, B. L., Karin, M., Martial, J. A. and Baxter, J. D. A method for isolation of intact, translationally active RNA. DNA (NY), 2: 329-335, 1983.
22. Fort, P., Marty, L., Piechaczyk, M., El Sabrouty, S., Dani, C., Jeanteur, P. and Blanchard, J. M. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate dehydrogenase multigenic family. Nucleic Acids Res., 13: 1431-1442, 1985.
23. Nash, T. The coloric estimation of formaldehyde by means of the Hantzsch reaction. Biochem. J., 55: 416-21, 1953.
24. Miners, J. O., Smith, K. J., Robson, R. A., McManus, M. E., Veronese, M. E. and Birkett, D. J. Tolbutamide hydroxylation by human liver microsomes. Biochem. Pharmacol., 37: 1137-1144, 1988.
25. Bertault-Pérès, P., Bonfils, C., Fabre, G., Just, S., Cano, J. P. and Maurel, P. Metabolism of cyclosporin A. II. Implication of macrolide antibiotic inducible cytochrome P4503c from rabbit liver microsomes. Drug Metab. Dispos., 75: 391-398, 1987.
26. Bonfils, C., Dalet, C. Dalet-Beluche, I. and Maurel, P. Cytochrome P450 isozyme LM3b from rabbit liver microsomes. J. Biol. Chem., 258: 5358-5362, 1983.
27. Bonfils, C., Dalet-Deluche, I. and Maurel, P. Triacethyloleandomycin as inducer of cytochrome P4503c from rabbit liver microsomes. Biochem. Pharmacol., 34: 2445-2450, 1985.
28. Daujat, M., Pichard, L., Dalet, C., Larroque, C. Bonfils, C., Pompon, D., Guzelian, P. S. and Maurel, P. Expression of five forms of microsomal cytochrome P450 in primary culture of rabbit hepatocytes treated with various classes of inducers. Biochem. Pharmacol., 36: 3597-3606, 1987.
29. Laemmli, V. K. Cleavage of structure proteins during the assembly of the head bacteriophage 14. Nature (Lond.), 227: 680-685, 1970.
30. Zhou, X. J., Martin, M., Placidi, M., Cano, J. P. and Rahmani, R. In vivo and in vitro pharmacokinetics and metabolism of Vinca alkaloids in rat. II. Vinblastine and vincristine. Eur. J. Drug Metab. Pharmacokinet., 15: 323-332, 1990.
31. Gelboin, H. V. Benzo(a)pyrene metabolism, activation, and carcinogenesis: role and regulation of mixed function oxidases and related enzymes. Physiol. Rev. 60:1107- 1166, 1980.
32. Robson, R. A., Mathews, A. P., Miners, J. O., McManus, M. E., Meyer, U. A., Hall, P. and Birkett, D. J. Characterization of theophylline metabolism in human liver microsomes. Br. J. Clin. Pharmacol., 24: 293-300, 1987.
33. Knodell, R. G., Raghvendra, K. D., Wilkinson, G. R. and Guengerich, F. P. Oxidation metabolism of hexobarbital in human liver: relationship to polymorphic S-mephe-nytoin 4-hydroxilation. J. Pharmacol. Exp. Then, 245: 845-849, 1988.
34. Distlerath, L. M., Reilly, P. E. B., Martin, M. V., Davis, G. G., Wilkinson, G. R. and Guengerich, F. P. Purification and characterization of the human liver cytochrome P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 260: 9057-9067, 1985.
35. Morgan, E. T., Koop, D. R. and Coon, M. J. Catalytic activity of cytochromes of ethanol treated rabbits: oxidation of alcohols. J. Biol. Chem., 257: 13951-13957, 1982.
36. Watkins, P. B., Wrighton, S. A., Maurel, P., Schuetz, E. G., Mendez-Picon, G., Parker, G. A. and Guzelian, P. S. Identification of an inducible form of cytochrome P450 in human liver. Proc. Natl. Acad. Sci. USA, 82: 6310-6314, 1985.
37. Combalbert, J., Fabre, I., Fabre, G., Dalet, I., Derancourt, J., Cano, J. P. and Maurel, P. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab. Dispos., 17: 197-207, 1989.
38. Guengerich, F. P., Muller Enoch, D. and Blair, I. A. Oxidation of quinidine by human liver cytochrome P450. Mol. Pharmacol., 30: 287-295, 1986.
39. Guengerich, F. P., Martin, M. V., Beaune, P., Kremers, P., Wolff, T. and Waxman, D. J. Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem., 257: 5051-5060, 1986.
40. Kronbach, T., Fisher, V. and Meyer, U. A. Cyclosporin metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporin metabolizing enzyme explains interactions of cyclosporin with other drugs. Clin. Pharmacol. Ther., 43: 630-635, 1988.
41. Zhou, X. J., Zhou-Pan, X. R., Gauthier, T., Placidi, M., Maurel, P. and Rahmani, R. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interaction. Biochem. Pharmacol., 45: 853-861, 1993.
42. Nelson, R. L., Dyke, R. W. and Root, M. A. Comparative pharmacokinetics of vindesine, vincristine, and navelbine in patients with cancer. Cancer Treat. Rev., 7: 17-24, 1980.
43. Johnson, I. S., Armstrong, J. G., Gorman, M. and Burnett, J. P. The Vinca alkaloids: a new class of oncolytic agents. Cancer Res., 23: 1390-1427, 1963.
44. Watkins, P., Murray, S. A., Winkelman, L. G., Heuman, D. M., Wrighton, S. A. and Guzelian, P. S. The erythromycine breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J. Clin. Invest., 83: 688-697, 1989.
45. Lucey, M. R., Kolars, J. C., Merio, R. M., Campbell, D. A., Aldrich, M. and Watkins, P. B. Cyclosporin toxicity at therapeutic blood levels and cytochrome P450IIIA. Lancet, 335: 11-15, 1990.
46. Neumayer, H. H. and Wagner, K. Diltiazem and the economic use of cyclosporin. Lancet, 2: 523, 1986.